Anemia's Impact on Glycemic Control

Mechanisms and Effects

Iron deficiency anemia prolongs erythrocyte lifespan, exposing red blood cells to glucose for longer periods, resulting in falsely elevated HbA1c levels that don't accurately reflect true glycemic control 1
Hemolytic anemia and other conditions that shorten erythrocyte lifespan can cause falsely low HbA1c values, potentially masking poor glycemic control 1, 2

The American Diabetes Association and other guideline societies recommend that HbA1c should be interpreted with caution in patients with known or suspected anemia 1, 2
When HbA1c results seem discordant with clinical presentation or self-monitoring blood glucose results, consider anemia as a potential confounding factor 3, 4
In patients with diabetes and anemia, especially those with advanced kidney disease, alternative methods for monitoring glycemic control, such as fructosamine and glycated albumin, should be considered 2, 5

Fructosamine and glycated albumin may be more reliable in patients with anemia, as they are not affected by red blood cell lifespan 2, 6
Self-monitored blood glucose (SMBG) and continuous glucose monitoring (CGM) provide direct measurements of blood glucose unaffected by anemia 6, 4

The American College of Physicians recommends screening for anemia in patients with diabetes, particularly when HbA1c values don't correlate with other glycemic measures 3
In patients with known anemia, consider more frequent SMBG or CGM to guide diabetes management decisions 6, 4
For patients with advanced kidney disease and anemia, consider less strict glycemic targets (HbA1c 7-8%) due to the unreliability of HbA1c and increased risk of hypoglycemia 2, 6

When iron deficiency is corrected through supplementation, HbA1c typically decreases by 0.5-0.7% as new red blood cells are formed with normal lifespans, according to the American Journal of Kidney Diseases 7, 8
CKD stage 2 has no clinically significant impact on A1C accuracy, with modest changes in the glucose-HbA1c relationship only becoming apparent with decreasing eGFR from 75 to 15 mL/min/1.73 m², as reported by the American Journal of Kidney Diseases 7, 8
In patients with CKD stages 3-4, A1C may underestimate glycemia, with slightly higher glucose levels than expected for given HbA1c levels, according to the American Journal of Kidney Diseases 7, 8
Reduced red blood cell lifespan from hemolysis or uremia can cause A1C to underestimate true glycemic control, as noted by the American Journal of Kidney Diseases 7, 9
Carbamylation of hemoglobin from uremia in advanced CKD can falsely elevate A1C, as reported by the American Journal of Kidney Diseases 7, 9
For a patient with CKD stage 2, HbA1c remains the best clinical marker of long-term glycemic control when combined with self-monitoring of blood glucose, according to the American Journal of Kidney Diseases 7, 8
Alternative markers like fructosamine, glycated albumin, or continuous glucose monitoring should be considered when eGFR falls below 30 mL/min/1.73 m² (CKD stages 4-5), as suggested by the American Journal of Kidney Diseases 7, 8